Specifically, it was shown that at environmentally relevant levels of BPA (1 nM), this agent is capable of binding and activating the mutant receptor to induce endogenous expression of PSA (prostate specific antigen, a known direct AR target), which is used clinically to monitor prostate cancer development and progression. Here, KLK3 is linked to prostate cancer.